A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia

Thrombosis and Haemostasis

Volumn 85, Issue 6, 2001, Pages 950-957

  Farner, B ^a   Eichler, P ^a   Kroll, H ^a   Greinacher, A ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Heparin induced thrombocytopenia; Heparinoid; Hirudin; Thrombocytopenia

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8A; DANAPAROID; HEPARIN; LEPIRUDIN;

ADULT; AMPUTATION; ANTICOAGULATION; ARTICLE; BLEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUESTIONNAIRE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

EID: 0034966778     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615946     Document Type: Article

References (33)

1. Heparin-induced thrombocytopenia: Towards consensus
2. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
3. Clinical picture of heparin-induced thrombocytopenia
4. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases
5. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia
6. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
7. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
8. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation
9. A 14-year study of heparin-induced thrombocytopenia
10. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets
11. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
12. Immune endothelial-cell injury in heparin-associated thrombocytopenia
13. Plasma P-selectin is increased in thrombotic consumptive platelet disorders
14. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
15. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
16. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
17. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators
18. Limitations of conventional treatment options for heparin-induced thrombocytopenia
19. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
20. Heparin-induced thrombocytopenia-pathogenesis and treatment
21. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
22. Low molecular weight heparinoid and heparin-induced thrombocytopenia
23. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172)
24. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Proceedings of a workshop held in London. 1996 Nov 1
25. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia
26. New treatment options for heparin-induced thrombocytopenia
27. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia
28. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
29. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA
30. Cox-regression
31. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia
32. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: Absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT